All News

SI.Sacroiliitis.AS_.jpg

Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

d Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
VitD_1.jpg

Best of 2024: Consensus Statements on Vitamin D

d Jack Cush, MD

The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. Interestingly, optimal levels of 25-hydroxy vitamin D (25(OH)D) are still being debated.

Read Article
vaccine.jpg

Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients

d Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
obesity.knee_.arthritis.jpg

Best of 2024: Pain Reduction with Methotrexate in Knee Osteoarthritis

d Jack Cush, MD

The Annals of Internal Medicine reports that oral, low dose, weekly methotrexate significantly reduced knee osteoarthritis pain, stiffness, and function in a randomized controlled trial.

Read Article
lung,cancer,blue,mass

Best of 2024: Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease

d Jack Cush, MD

A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).

Read Article
pills-384846_640%20%281%29.jpg

Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis

d Jack Cush, MD

A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate analgesic prescription annual prevalence in patients with RA, PsA and axSpA and found that analgesic prescribing declined over time but remained common.

Read Article
Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis https://t.co/iQrBVzWaI8 https://t.co/Rx86Q57oEZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Bah Humbug Vitamin D (12.20.2024) https://t.co/Mjuk6buRsX https://t.co/aX8cetkbWc

Links:

Dr. John Cush RheumNow ( View Tweet)
If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/0bwfgNnB0e

Links:

Dr. John Cush RheumNow ( View Tweet)

To Behcet’s or not to Behcet’s? -Aphtous ulcers have unique features(broad ddx) -Oral+Genital ulcers=CAP not necessary BD. -Pathergy test ⬆️specific and not limited to skin! -Pulmonary arterial aneurysms=almost pathognomonic. -Do not get confused by HLAs. #ACR24 @RheumNow… https://t.co/3nWgILNVYw

Dr. John Cush RheumNow ( View Tweet)

A Fibroblast Renaissance Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/GQXWkqMkIW https://t.co/W6UXT4HCeg

Links:

Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/8wvSy8555Z https://t.co/vaGt1AylBr

Links:

Dr. John Cush RheumNow ( View Tweet)
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/AsZ9CU2TZU https://t.co/TP1TMqotqi

Links:

Dr. John Cush RheumNow ( View Tweet)
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/m7VL6HHdUN https://t.co/i3knGVQYvj
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/yHo5BNlbiL https://t.co/R2je32YYGy

Links:

Dr. John Cush RheumNow ( View Tweet)
Palliative Care in Rheumatology Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/fqx8wGLTqI https://t.co/5mwJx3ZN6u

Links:

Dr. John Cush RheumNow ( View Tweet)
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush RheumNow ( View Tweet)
Biomarker Study of 171 synovial fluid samples (54 primary OA, 57 RA, 30 Crystal,30 septic arthritis) examined the cartilage oligomeric matrix protein (COMP) to IL-8 ratio and found it can differentiate primary OA and inflamm arthritis w/ sensitivity 87% and specificity 89%… https://t.co/UH77DFgAlJ https://t.co/MfXQcl0BhW
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Prescription Painkiller Misuse in Chronic Pain Patients https://t.co/AyccRCuAHh https://t.co/RYuvDwHANo

Links:

Dr. John Cush RheumNow ( View Tweet)
Abuse of the Safety-Net 340B Drug Programs Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×